Showing results (11-20 of 66) with videos related to
Sort By:
Pageof 7
Seminars in Hematology|July 15, 2005
Alternative treatments for myelodysplastic syndromesMikkael Sekeres, Alan ListFuture Oncology (London, England)|March 25, 2006
Lenalidomide: an immunomodulatory drugEdward Crane, Alan ListVitamins and Hormones|June 21, 2017
Erythropoietin Receptor Signaling and Lipid RaftsKathy McGraw, Alan ListCurrent Hematologic Malignancy Reports|April 29, 2010
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?Mikkael A Sekeres, Alan ListBlood|January 24, 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromesDavid A Sallman, Alan ListBest Practice & Research. Clinical Haematology|September 26, 2006
Immunomodulation in myelodysplastic syndromesMikkael A Sekeres, Alan ListCurrent Hematology Reports|May 4, 2005
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Mikkael A Sekeres, Alan ListCurrent Oncology Reports|August 20, 2022
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric OncologyLodovico Balducci, Claire Falandry, Alan ListSeminars in Hematology|September 30, 2017
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyondChetasi Talati, David Sallman, Alan ListDrugs & Aging|January 30, 2023
A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle ArrestLodovico Balducci, Claire Falandry, Alan ListPageof 7